Addario Lung Cancer Medical Institute (ALCMI)

At ALCMI, our hearts are in the research. This Valentine’s Day, we celebrate the incredible patients, families, and researchers who inspire us every day. #lungcancer

Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models KRAS G12D and G12C produce lung tumors with distinct microenvironmental and growth features that influence progression and survival.

KRAS allele identity dictates the fundamental biology of lung cancer, as William Hai-Cheng Huang MD, and colleagues demonstrate that G12C and G12D mutations diverge in oncogenic potency, immune engagement, and relapse kinetics. #lungcancer
www.science.org/doi/10.1126/...

Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association | Stroke About 10% to 15% of patients with ischemic stroke have a history of cancer, half of whom have active malignancy at the time of stroke. With improved cancer treatments extending patient survival, the…

Metastatic lung cancer and adenocarcinoma histology are among the strongest predictors of acute ischemic stroke, according to a new American Heart Association scientific statement that defines cancer-related stroke as a distinct, high-risk clinical entity. #lungcancer

Summit’s Potential Keytruda Rival Gets November FDA Decision Date The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

Save the date! Summit Therapeutics, Inc.s’ PD-1/VEGF bispecific ivonescimab now has an FDA decision date of November 14 for EGFR-mutant, locally advanced or metastatic non-squamous NSCLC. #lungcancer
www.biospace.com/fda/summits-...

Treating Lung Cancer Patients Earlier in Day Improves Outcomes Research shows that people with advanced lung cancer can benefit from having immunochemotherapy treatment before 3pm.

New research shows that timing first-line chemo-immunotherapy earlier in the day significantly improves survival outcomes for patients with advanced non-small cell lung cancer. #lungcancer
www.insideprecisionmedicine.com/topics/oncol...

Zenocutuzumab, the first-in-class HER2/HER3 bispecific, has shown durable responses and meaningful progression-free survival in the phase 2 eNRGy trial for NRG1 fusion–positive advanced NSCLC. #lungcancer
www.oncologynewscentral.com/nsclc/first-...

Demystifying a new tool for early lung cancer detection Bayhealth’s mobile classroom lets students and neighbors explore Ion robotic bronchoscopy, boosting awareness, screening and career interest.

Kudos to the American Medical Association for shining a light on an innovative approach to lung cancer detection and treatment! #lungcancer
www.ama-assn.org/public-healt...

Lung cancer survivors at risk for non-lung secondary cancer years after definitive therapy Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary malignancies years after definitive local therapy.A retrospective evaluation of…

Lung cancer survivors face a meaningful long‑term risk of non‑lung secondary cancers years after curative therapy, according to new data. #lungcancer
www.healio.com/news/hematol...

Today, we recognize #WorldCancerDay, and we recommit to our mission to make lung cancer a survivable disease. Have an idea for a clinical trial? Let's talk and get to work! #lungcancer

Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage - Cell Death & Differentiation Cell Death & Differentiation - Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage

Oncogenic p53 in lung cancer does more than disrupt genome integrity. A new study shows that mutant, gain-of-function p53 actively drives a replication-based loop that both accelerates tumor growth and creates a targetable vulnerability. #lungcancer
www.nature.com/articles/s41...

The American College of Radiology, the American Society for Radiation Oncology (ASTRO), and The Society of Thoracic Surgeons have issued a rare joint statement to correct "misinformation" and methodological flaws that distort the perceived risks of lung cancer screening. #lungcancer

Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection - OncoDaily Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection / AI in healthcare, AI in Radiology, Artificial Intelligence in

New partnership alert! Bristol Myers Squibb and Microsoft have formed a new strategic partnership to use FDA-cleared radiology AI to detect lung cancer earlier and at scale. #lungcancer
oncodaily.com/techology/br...

Cancer Center investigator targets key enzyme complex to treat KRAS-mutated lung cancer The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex...

Tom Cunningham, PhD, at the University of Cincinnati Cancer Center, is targeting the PRPS enzyme complex as a therapeutic dependency in KRAS-mutated lung cancer, backed by a two-year, $150,000 Lung Cancer Research Foundation grant. #lungcancer
www.uc.edu/news/article...

Associations between Prior Lung Diseases and Risk of Lung Cancer in Populations With No Smoking History: A Systematic Review and Meta-Analysis - PubMed History of TB and CB were associated with increased lung cancer risk among populations with no smoking history. Future studies examining these associations should analyze more diverse populations and...

A history of tuberculosis and chronic bronchitis increases lung cancer risk in people who have never smoked, according to a new systematic review. #lungcancer
pubmed.ncbi.nlm.nih.gov/41534708/

Gut bacteria molecule boosts lung cancer treatment response - UF Health GAINESVILLE, Fla. — UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to…

Christian Jobin, Ph.D., and Rachel Newsome, Ph.D., at UF Health Cancer Institute have identified a gut microbiota–derived metabolite, Bac429, that materially increases immunotherapy activity in lung cancer models and is now being advanced into a drug candidate. #lungcancer

New Research May Reveal Why Lung Cancer and COPD Overlap Dr. Catherine Sears’ research seeks to change the way COPD and lung cancer are treated.

Catherine Sears, MD, and colleagues at Indiana University are linking impaired DNA repair to the shared biology of emphysema and lung cancer. #lungcancer
www.lung.org/blog/copd-lu...

Zoldonrasib just became the first investigational KRAS G12D targeted therapy in NSCLC to receive FDA Breakthrough Therapy Designation, based on Phase 1 monotherapy data from Revolution Medicines. #lungcancer
ir.revmed.com/news-release...

Basal stem cells, not neuroendocrine cells, may be the initiating cell of origin for small-cell lung cancer, according to Trudy Oliver. #lungcancer
www.dukechronicle.com/article/duke...

Olvi-Vec delivered durable systemic activity in platinum-relapsed lung cancer, with up to 85% tumor shrinkage reported by Genelux in interim trial data published by RTTNews. #lungcancer
www.nasdaq.com/articles/gen...

FDA Approves Six New Cancer Therapies in December 2025 | CURE The FDA approved six new therapies for blood, prostate and lung cancers and supportive care, expanding treatment options based on recent trials.

Six FDA approvals in December 2025 expanded the oncology toolbox across blood cancers, prostate cancer, lung cancer, and supportive care, as reported in Cure. #lungcancer
www.curetoday.com/view/fda-app...

Datroway’s Tropion-Lung01 do-over? “I am very impressed - it has become my go-to platform”

Check this out! AstraZeneca is re-running Datroway in relapsed NSCLC with a biomarker-enriched phase 3 design that directly addresses the Tropion-Lung01 miss. #lungcancer
www.oncologypipeline.com/apexonco/dat...

A large-scale study from the Genetic Epidemiology of Lung Cancer Consortium, led by Yanhong Liu and published in the Journal of Thoracic Oncology, identifies rare, high-penetrance germline variants that materially elevate familial lung cancer risk. #lungcancer
www.jto.org/article/S155...

Inflammation fuels one of the most aggressive forms of lung cancer Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to…

Inflammation is emerging as a primary engine of progression in small cell lung cancer. #lungcancer
medicalxpress.com/news/2025-12...

Patterns of lung cancer incidence in adults diagnosed under age 50 in the United States, 2000–2021 Early-onset lung cancer incidence declined overall from 2000 to 2021, except for persistent or rising LUAD among Asian and Hispanic females, which implicates emerging non-tobacco risk factors and highlights the need for targeted prevention.

Early-onset lung cancer incidence in the United States is falling overall, but not for lung adenocarcinoma in young Asian and Hispanic women, according to a new SEER-based analysis. #lungcancer
acsjournals.onlinelibrary.wiley.com/doi/abs/10.1...

Dr Sands on Challenges in the Diagnosis and Management of LEMS in SCLC | OncLive Jacob Sands, MD, discusses challenges in the diagnosis and management of LEMS in patients with small cell lung cancer.

LEMS in small cell lung cancer remains under-recognized and frequently misattributed to treatment-related toxicity, as highlighted by our friend Dr. Jacob Sands, MD, in a recent OncLive commentary. #lungcancer
www.onclive.com/view/dr-sand...

A new phase 3 report in the NEJM Group shows that adding platinum-pemetrexed chemotherapy to first-line osimertinib improves overall survival in EGFR-mutated advanced NSCLC. #lungcancer
www.nejm.org/doi/abs/10.1...

FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery | Pharmacy Times FDA approves Rybrevant Faspro, a groundbreaking subcutaneous therapy for EGFR-mutated lung cancer, enhancing patient comfort and survival rates.

Amivantamab plus hyaluronidase-lpuj (Rybrevant Faspro) has just become the first and only subcutaneous EGFR-targeted therapy for EGFR-mutated NSCLC. #lungcancer
www.pharmacytimes.com/view/fda-app...

How Doctors Are Making Lung Nodules Glow in the Dark Uterine fibroid embolization is a minimally invasive treatment for fibroids. Discover how the UFE procedure works and how it compares to other treatments.

City of Hope thoracic surgeons are using the fluorescent imaging agent Cytalux (pafolacianine) to make lung nodules “glow in the dark,” improving intraoperative identification of cancerous lesions in patients undergoing lung nodule surgery. #lungcancer
www.cityofhope.org/hope-matters...

OncoPrism-NSCLC Test Predicts Key Clinical Outcomes in Lung Cancer | CancerNetwork OncoPrism-NSCLC was found to be a predictive biomarker of immune checkpoint inhibitor benefit vs a general prognostic tool in patients with NSCLC.

The OncoPrism-NSCLC test has been validated as a superior predictive biomarker for immunotherapy benefit in advanced lung cancer according to new data from Cofactor Genomics and the PREDAPT trial. #lungcancer
www.cancernetwork.com/view/oncopri...

Study finds a new protein target against KRAS-driven non-small cell lung cancer Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States.

University of Michigan Rogel Cancer Center investigators have defined PP2A stabilization by the molecular glue RPT04402 as a new protein target to overcome KRAS-driven non-small cell lung cancer. #lungcancer
www.news-medical.net/news/2025121...